Cargando…
Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
BACKGROUND: The ST6Gal-I sialyltransferase is upregulated in numerous cancers, and high expression of this enzyme correlates with poor patient prognosis in various malignancies, including ovarian cancer. Through its sialylation of a select cohort of cell surface receptors, ST6Gal-I modulates cell si...
Autores principales: | Britain, Colleen M., Holdbrooks, Andrew T., Anderson, Joshua C., Willey, Christopher D., Bellis, Susan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800010/ https://www.ncbi.nlm.nih.gov/pubmed/29402301 http://dx.doi.org/10.1186/s13048-018-0385-0 |
Ejemplares similares
-
Regulation of inflammatory signaling by the ST6Gal-I sialyltransferase
por: Holdbrooks, Andrew T., et al.
Publicado: (2020) -
Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics
por: Ankenbauer, Katherine E., et al.
Publicado: (2023) -
Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics
por: Ankenbauer, Katherine E., et al.
Publicado: (2023) -
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells
por: Schultz, Matthew J, et al.
Publicado: (2013) -
ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression
por: Bhalerao, Nikita, et al.
Publicado: (2023)